Likely Delay for Janssen’s Sirukumab Sets up Head to Head Battle Between Roche/Genentech’s Actemra and Sanofi/Regeneron’s Kevzara in the US Rheumatoid Arthritis Market
Despite Kevzara’s aggressive pricing play, early launch metrics of the newest IL-6 inhibitor, indicate conservative uptake, according to Spherix Global Insight’s most recent quarterly update Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — Following an unfavorable recommendation from the FDA’s Arthritis Advisory Committee, it is unlikely that sirukumab will gain approval anytime in […]
Janssen’s Tremfya (guselkumab) Makes its Debut in the Psoriasis Market and Early Dermatologist Feedback Reveals that Distinction from Stelara and the IL-17 Inhibitors will be Key to Success
According to recent data released from Spherix Global Insights, early US dermatologist’s views of Tremfya leave ground to be covered Download Report Overview EXTON, Pa., Aug. 9, 2017 /PRNewswire/ — At two weeks post launch, only half of the surveyed US dermatologists (n=104) were aware of Tremfya’s approval when aided. Furthermore, less than one in […]
New Study of More Than 1,000 Dialysis Patients Reveals Significant Opportunity for Improvement of Hyperphosphatemia and Highlights the Potential for Amgen’s Parsabiv
According to a new study published by Spherix Global Insights, close to half of the dialysis patients treated with phosphate binders are above the target phosphorus level Download Report Overview EXTON, Pa., Aug. 3, 2017 /PRNewswire/ — According to the latest RealWorld Dynamix: Dialysis report, more than one-third of the dialysis patients were above target […]
RealWorld Dynamix™: Dialysus US 2017
The management of renal anemia in dialysis patients as well as in those with later stage chronic kidney disease is becoming increasingly complex. In the dialysis setting, clinical management is further complicated by a reimbursement model that treats commonly used therapies like erythropoiesis stimulating agents (ESAs) and iron therapies as cost centers. Novel products in […]
Can Pharma Companies Expand the Current Ankylosing Spondylitis (AS) Market with a New Indication for Non-Radiographic Axial Spondyloarthropathy (nr-axSpA)? Novartis and UCB Pharma Are Just Two Companies Angling to Bring Approved Treatments to These Patients in the Near Future
According a new report from Spherix Global Insights, biologic treatment of nr-axSpA is complicated by multiple factors resulting in a significantly lower percentage of patients with nr-axSpA being treated compared to those with AS Download Report Overview EXTON, Pa., Aug. 1, 2017 /PRNewswire/ — An independent study conducted by Spherix Global Insights in June with […]
MS News That Caught My Eye This Week: Ocrevus and Insurance, Intimacy Issues, Breastfeeding
From: Multiple Sclerosis News Today By: Ed Tobias Read more here.
Early Uptake of Roche/Genentech’s Ocrevus Off to Stellar Start, According to Latest Quarterly Update from Spherix Global Insights
The Q2 edition of RealTime Dynamix™: Multiple Sclerosis finds that trial rates for Ocrevus are in-line with pre-launch estimates and robust uptake of the drug is anticipated in the next six months Download Report Overview July 19, 2017 – Exton, PA – For the past year, neurologists have been reporting high anticipation for Roche/Genentech’s Ocrevus […]
RealTime Dynamix™: Ankylosing Spondylitis & Non-radiographic Axial Spondyloarthritis US Q2
Use of biologics in the management of axial spondyloarthropathies (axSpA) has become well established in psoriatic arthritis and ankylosing spondylitis (AS). The spectrum of axSpA is becoming better understood and now includes inflammation in the absence of observable damage using radiographic techniques (nr-axSpA). In nr-axSpA, the impact on quality of life is rated as high, […]
Pfizer’s Inflectra, Takeda’s Entyvio, and Janssen’s Simponi Projected to Gain Ground in the Increasingly Competitive Ulcerative Colitis Market
According to the latest quarterly update from Spherix Global Insights, US gastroenterologists are gearing up for near term change Download Report Overview EXTON, Pa., July 7, 2017 /PRNewswire/ — Results from a recent study just released by Spherix Global Insights reveal that US gastroenterologists (n=103) project significant growth of Takeda’s Entyvio, Janssen’s Simponi, and Pfizer/Hospira’s […]
BMS’ Orencia Plunges into the Fray of Battle for Alternative MOA for Psoriatic Arthritis with Recent FDA Approval…. Can it Find a Unique Space to Play?
Approval of Orencia for Psoriatic Arthritis (PsA) opens door for expansion of use based on existing off-label experience, adding further challenge to Novartis’s Cosentyx and Janssen’s Stelara for preferred TNF alternative, according to recent reports from Spherix Global Insights. Download Report Overview EXTON, Pa., July 6, 2017 /PRNewswire/ — BMS’ Orencia, already indicated for Rheumatoid […]